Sales forces dwindle at top pharmas

Share this article:
In an Associated Press tally, seven out of the 12 companies surveyed reported reductions in work force by 10% or more since January 2007.  

Respondents included Pfizer, Johnson & Johnson and AstraZeneca. Schering-Plough and Wyeth have both made recent announcements regarding job cuts in their sales departments.

According to Craig Scott, CEO of TargetRx, reducing sales forces may not be the best way to foster industry convalescence, but it should shift the focus away from basic “activity levels,” toward a more optimal sales performance: quality products presented to physicians in a quality way.

“Cost cutting through sales and marketing layoffs is convenient in the short term but won't solve the root problem for pharmaceutical companies. The work that we have done at TargetRx indicates that improving the quality of sales and marketing yields almost five times more of an increase in physician prescribing than increasing the volume of sales and marketing activity. This underscores a clear opportunity for any company that needs to reduce spending.” 
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Features

Email Newsletters

More in Features

Journal Ad Review: Reality Bites

Journal Ad Review: Reality Bites

Print's numbers may be taking some small steps in the right direction, but data is what the industry really wants to sink its teeth into. Larry Dobrow reports on what ...

Headliner: Proteus CEO takes an original path

Headliner: Proteus CEO takes an original path

Andrew Thompson, CEO, Proteus Digital Health

Leadership Exchange: How Do We Get Beyond the Pill?

Leadership Exchange: How Do We Get Beyond the ...

As its focus moves from manufacturing to service, pharma needs to partner with healthcare neophytes as well as established players. James Chase asks six experts to assess the risks and ...